Entecavir Prophylaxis for Hepatitis B Reactivation for CD20 Positive B-cell Lymphoma Patients With Resolved Hepatitis B (Negative Hepatitis B Surface Antigen, Positive Hepatitis B Core Antibody) — REHEB  

CD20 Positive B-cell Lymphoma Clinical Trial

Official title: Entecavir Prophylaxis for Hepatitis B Reactivation for CD20 Positive B-cell Lymphoma Patients With Resolved Hepatitis B (Negative Hepatitis B Surface Antigen, Positive Hepatitis B Core Antibody) (REHEB)：a Single Arm, Open Label, Multi-center Phase II Study

Status Recruiting

Clinical Trial Summary

This phase 2 trial aims to evaluate the efficacy of entecavir prophylacxis for hepatitis B virus (HBV) reactivation that continues until 6 months after completing CD20 monoclonal antibody therapy in patients with CD20-positive B-cell lymphomas and resolved hepatitis B (negative hepatitis B surface antigen, positive hepatitis B core antibody).

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Hepatitis
• Hepatitis A
• Hepatitis B
• Lymphoma
• Lymphoma, B-Cell

• NCT number: NCT05453435
• Study type: Interventional
• Source: Sun Yat-sen University
• Contact: Qingqing Cai, PhD
• Phone: 0086-20-87342823
• Email: caiqq@sysucc.org.cn
• Status: Recruiting
• Phase: Phase 2
• Start date: July 15, 2022
• Completion date: July 2025